#1 Clinical Trials Search in Europe

Belzupacap Sarotalocan

A groundbreaking Phase 3 clinical trial is underway to assess the effectiveness and safety of Belzupacap Sarotalocan (AU-011) in treating primary indeterminate lesions or small choroidal melanoma. This innovative drug, administered through a unique suprachoroidal injection method, offers hope for patients with these rare eye conditions. The study aims to compare the drug’s performance against a sham control, potentially paving the way for a new treatment option in ocular oncology.

Table of Contents

What is Belzupacap Sarotalocan?

Belzupacap Sarotalocan, also known by its product code AU-011, is a new medication being studied for the treatment of certain eye conditions[1]. It is classified as an orphan drug, which means it is developed to treat rare medical conditions[1]. This medication is currently undergoing clinical trials to evaluate its effectiveness and safety.

Medical Conditions Treated

Belzupacap Sarotalocan is being investigated for the treatment of two main conditions[1]:

  • Primary Indeterminate Lesions (IL): These are suspicious growths in the eye that doctors are unsure about. They could potentially develop into cancer.
  • Small Choroidal Melanoma (CM): This is a type of eye cancer that develops in the choroid, a layer of blood vessels in the eye. “Small” refers to the early stages of this cancer.

Both of these conditions affect the choroid, which is an important part of the eye responsible for providing blood and nutrients to the outer layers of the retina[1].

How is it Administered?

Belzupacap Sarotalocan is administered in a unique way[1]:

  • It is given as a solution for injection.
  • The medication is injected into the suprachoroidal space (SCS) of the eye. This is a space between two layers at the back of the eye.
  • A special device called the Clearside SCS Microinjector is used to deliver the medication precisely into this space.

This method of administration allows the medication to be delivered directly to the area of the eye where it’s needed, potentially improving its effectiveness and reducing side effects in other parts of the body.

Clinical Trial Details

A Phase 3 clinical trial is currently underway to evaluate Belzupacap Sarotalocan[1]. Here are some key details about the trial:

  • It’s a randomized, masked, controlled trial. This means that participants are randomly assigned to either receive the actual medication or a placebo (sham injection), and neither the participants nor the researchers know who is receiving which.
  • The trial aims to determine the efficacy (how well it works) and safety of Belzupacap Sarotalocan compared to a sham control.
  • The study will also assess how the drug moves through the body (pharmacokinetics) and how the immune system responds to it (immunogenicity).

Eligibility Criteria

To participate in the clinical trial, patients must meet certain criteria[1]. Some of the main inclusion criteria are:

  • Having a clinical diagnosis of primary indeterminate lesion or small choroidal melanoma with documented early growth
  • No evidence of metastatic disease (cancer that has spread to other parts of the body)
  • Being treatment-naïve for their condition (not having received previous treatment)

Some exclusion criteria (reasons why a person might not be able to participate) include:

  • Any active eye infection or other eye disease in the study eye
  • Known contraindications or sensitivities to the study drug or laser
  • History of certain eye surgeries or procedures that could affect the administration of the drug

Expected Outcomes

The main goals of the treatment and what researchers hope to achieve include[1]:

  • Primary endpoint: Measuring the time it takes for the tumor to progress. This will be assessed at Week 65 of the study.
  • Secondary endpoint: Measuring the time it takes to reach a composite endpoint, which includes either tumor progression or visual acuity failure (loss of vision).

These outcomes will help determine how effective Belzupacap Sarotalocan is in treating the targeted eye conditions and preserving vision.

Safety and Side Effects

As with any new medication, safety is a primary concern in the clinical trial[1]. While specific side effects are not mentioned in the provided information, the study is designed to carefully monitor and assess the safety of Belzupacap Sarotalocan. Patients in the trial will be closely monitored for any adverse effects.

It’s important to note that the maximum daily dose being studied is 80 micrograms, with a maximum total dose of 240 micrograms over a treatment period of up to 3 months[1]. This information helps researchers ensure the medication is being used safely and effectively.

Aspect Details
Drug Name Belzupacap Sarotalocan (AU-011)
Condition Studied Primary Indeterminate Lesions or Small Choroidal Melanoma
Trial Phase Phase 3
Administration Method Suprachoroidal injection using Clearside SCS Microinjector
Primary Endpoint Time to reach Tumor Progression (at Week 65 analysis)
Key Eligibility Criteria Clinical diagnosis of IL/CM with early growth, no metastatic disease, treatment-naïve
Orphan Drug Designation Yes (EU/3/22/2599)

FAQ

  • What is Belzupacap Sarotalocan and what is it used for? Belzupacap Sarotalocan (AU-011) is an investigational drug being studied for the treatment of primary indeterminate lesions or small choroidal melanoma, which are rare eye conditions. It is administered through a special injection method into the suprachoroidal space of the eye.
  • How is Belzupacap Sarotalocan administered in the clinical trial? The drug is administered using a device called the Clearside SCS Microinjector, which delivers Belzupacap Sarotalocan into the suprachoroidal space (SCS) of the eye. This unique method allows for targeted delivery of the medication to the affected area.
  • What are the main objectives of this clinical trial? The main objective is to determine the efficacy and safety of Belzupacap Sarotalocan compared to a sham control for treating primary indeterminate lesions and small choroidal melanoma. The study also aims to assess the drug's pharmacokinetics and immunogenicity when administered suprachoroidally.
  • Who is eligible to participate in this clinical trial? Eligible participants include those with a clinical diagnosis of primary indeterminate lesion or small choroidal melanoma showing early growth, no evidence of metastatic disease, and who are treatment-naïve for their condition. Certain exclusion criteria, such as active eye infections or contraindications to the study drug, may apply.
  • What are the primary endpoints of the study? The primary endpoint of the study is the time to reach Tumor Progression, which will be analyzed at Week 65. A secondary endpoint includes the time to reach a Composite Endpoint, which considers both tumor progression and visual acuity failure.

Ongoing Clinical Trials on Belzupacap Sarotalocan

  • Study on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Choroidal Melanoma: A type of eye cancer that develops in the choroid, a layer of blood vessels between the white of the eye (sclera) and the retina.
  • Indeterminate Lesion: An abnormal growth or spot in the eye that cannot be definitively classified as benign or malignant without further observation or testing.
  • Suprachoroidal Space (SCS): A potential space between the choroid and sclera of the eye, used as a route for drug delivery in this clinical trial.
  • Sham Control: A procedure that mimics the actual treatment but does not involve administering the active drug, used as a comparison in clinical trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Visual Acuity: The clarity or sharpness of vision, often measured using an eye chart.
  • Metastatic Disease: A condition where cancer has spread from its original site to other parts of the body.
  • Orphan Drug: A pharmaceutical product developed specifically to treat a rare medical condition.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-belzupacap-sarotalocan-for-patients-with-small-choroidal-melanoma-or-indeterminate-lesions/